According to a new report by Polaris Market Research, the global oncology clinical trials market was valued at USD 14.21 billion in 2024 and is projected to reach USD 23.50 billion by 2034, expanding at a CAGR of 5.17% over the forecast period. Growth is underpinned by rising global cancer incidence, expanding investment in oncology drug development, and accelerating adoption of biomarker-enabled, adaptive trial designs.

What Is Driving Oncology Clinical Trials Market Growth?

Demand is climbing as the WHO's projected rise in global cancer cases — from 20 million in 2022 to more than 35 million by 2050 — converges with growing pharmaceutical investment in targeted therapies and immunotherapies. Sponsors are prioritizing biomarker-enabled patient selection, pushing trial adoption across major oncology indications. Polaris analysts note that greater availability of capital positions the market for sustained growth through 2034, with lung cancer emerging as the largest revenue contributor and the thyroid cancer segment posting the fastest incremental gains.

Key Trends Shaping the Oncology Clinical Trials Industry

Biomarker-Enabled and Adaptive Trial Design

Pharmaceutical firms are placing emphasis on novel trial design, biomarker-enabled patient selection, and adaptive protocols to speed drug approval, reflecting a broader industry trend toward precision medicine and improved trial efficiency.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/oncology-clinical-trials-market

Regulatory Support and Multidisciplinary Care Integration

Healthcare institutions are incorporating oncology trials into multidisciplinary cancer-care programs, while regulatory bodies continue to support expedited pathways, weaving stronger regulatory landscape support into sponsor decision-making.

CRO Partnerships and Real-World Evidence

Market leaders are increasing partnerships with contract research organizations, hospitals, and academic institutions to tap real-world evidence, shaping a positive market outlook for observational and expanded-access study designs.

Market Segmentation: Breaking Down the Oncology Clinical Trials Market

Polaris segments the oncology clinical trials market by cancer type, phase, study design, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Cancer Type

The lung cancer segment led the market in 2024, reflecting its widespread global incidence — the American Cancer Society estimated approximately 226,650 new U.S. lung cancer cases in 2025 — while the thyroid cancer segment is projected to expand at the fastest CAGR through 2034 as early-detection programs and new targeted therapies emerge.

By Phase

The phase I segment led the market in 2024, driven by demand for initial dosage and safety testing of novel oncology treatments, while the phase II segment is expected to expand at the fastest CAGR as efficacy-evaluation demand and adaptive study designs shorten development timelines.

By Study Design

The interventional segment dominated the market in 2024, supported by government grants financing experimental-treatment evaluation, while the observational segment is expected to register the highest CAGR as real-world evidence and digital health platforms gain emphasis.

By Region

North America dominated the market in 2024, led by the U.S., owing to extensive research infrastructure and regulatory support, while Asia Pacific is projected to grow at the fastest rate, driven by rising cancer prevalence and expanding healthcare infrastructure across China and India.

Regional Outlook: Where Is Oncology Clinical Trials Growing Fastest?

North America dominated the oncology clinical trials market in 2024, led by the U.S., which benefits from extensive research infrastructure, strong regulatory support, and initiatives such as OneOncology and START's May 2025 launch of three new early-phase trial sites. Europe holds a substantial share, supported by strong regulatory frameworks — the European medicines network reported an average of 200 clinical trial submissions per month under CTR from January 2022 to January 2025. Asia Pacific is projected to post the highest growth rate, driven by rising cancer cases in India, where the ICMR reported more than 1.4 million new cancer cases in 2023, and China's rapidly expanding government-backed oncology research programs.

Competitive Landscape: Leading Oncology Clinical Trials Companies

Key players profiled in the report include Pfizer Inc., Novartis AG, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Johnson & Johnson, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., AbbVie Inc., Gilead Sciences, Inc., and Takeda Pharmaceutical Company Ltd., who are focusing on adaptive design studies, biomarker-based patient enrollment, and CRO partnerships to strengthen market position across the lung cancer and phase I/II segments outlined above. Recent moves include Johnson & Johnson's presentation of more than 70 studies at ASCO and EHA 2025 and Olema Oncology's September 2025 Phase 1b/2 partnership with Pfizer in ER+/HER2- metastatic breast cancer.

Why It Matters for Buyers Evaluating the Oncology Clinical Trials Market

For stakeholders researching the oncology clinical trials market, this report benchmarks market share, segment-level pricing, and forecast data — by cancer type, phase, study design, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing CRO partners, investors sizing entry points in targeted-therapy pipelines, and strategy teams tracking immunotherapy trials as a growth adjacency.

About Polaris Market Research

Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.

More Trending Latest Reports By Polaris Market Research:

Automated Guided Vehicle (Agv) Market

Mobile Accessories Market

Migraine Drugs Market

Hospital Electronic Health Records Market

Mobile Accessories Market

Stain Remover Products Market

Composites Market

Plastic Resins Market

Epigenetics Market